Dermapharm Holding Resultados de beneficios anteriores
Pasado controles de criterios 2/6
Dermapharm Holding ha aumentado sus beneficios a una tasa media anual de 1.8%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 12.9% anual. Los ingresos han ido creciendo a una tasa media de 11.3% al año. La rentabilidad financiera de Dermapharm Holding es de 15.2%, y sus márgenes netos son de 7.7%.
Información clave
1.8%
Tasa de crecimiento de los beneficios
1.8%
Tasa de crecimiento del BPA
Crecimiento de la industria Pharmaceuticals | 7.3% |
Tasa de crecimiento de los ingresos | 11.3% |
Rentabilidad financiera | 15.2% |
Margen neto | 7.7% |
Próxima actualización de resultados | 28 Mar 2025 |
Actualizaciones de resultados anteriores recientes
Recent updates
Here's Why Dermapharm Holding (ETR:DMP) Has A Meaningful Debt Burden
Sep 28Dermapharm Holding SE Beat Revenue Forecasts By 6.7%: Here's What Analysts Are Forecasting Next
Aug 31Dermapharm Holding SE's (ETR:DMP) P/E Still Appears To Be Reasonable
Aug 17It Looks Like Dermapharm Holding SE's (ETR:DMP) CEO May Expect Their Salary To Be Put Under The Microscope
Jun 21These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Extensively
Apr 29Dermapharm Holding SE's (ETR:DMP) Price In Tune With Earnings
Feb 07Dermapharm Holding (ETR:DMP) Seems To Use Debt Quite Sensibly
Dec 15An Intrinsic Calculation For Dermapharm Holding SE (ETR:DMP) Suggests It's 24% Undervalued
Nov 17Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet
Aug 28Dermapharm Holding SE's (ETR:DMP) Intrinsic Value Is Potentially 76% Above Its Share Price
Aug 01Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet
May 29Is Dermapharm Holding SE (ETR:DMP) Trading At A 44% Discount?
May 03Dermapharm Holding's (ETR:DMP) Soft Earnings Are Actually Better Than They Appear
Apr 04We Think Dermapharm Holding (ETR:DMP) Can Stay On Top Of Its Debt
Feb 22Is Dermapharm Holding (ETR:DMP) A Risky Investment?
Nov 17Is Dermapharm Holding (ETR:DMP) A Risky Investment?
Aug 16Is Dermapharm Holding (ETR:DMP) A Risky Investment?
May 18Is Dermapharm Holding (ETR:DMP) Using Too Much Debt?
Feb 17These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Reasonably Well
Nov 19Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?
Aug 21Is Dermapharm Holding SE (ETR:DMP) Trading At A 28% Discount?
Jul 31Is Dermapharm Holding SE (ETR:DMP) The Right Choice For A Smart Dividend Investor?
May 03Calculating The Intrinsic Value Of Dermapharm Holding SE (ETR:DMP)
Apr 16Here's Why Dermapharm Holding (ETR:DMP) Can Manage Its Debt Responsibly
Mar 25Did You Miss Dermapharm Holding's (ETR:DMP) Impressive 110% Share Price Gain?
Mar 07Is Dermapharm Holding SE's (ETR:DMP) 27% ROE Better Than Average?
Feb 15Something To Consider Before Buying Dermapharm Holding SE (ETR:DMP) For The 1.4% Dividend
Jan 29Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?
Dec 24The Dermapharm Holding (ETR:DMP) Share Price Has Gained 45% And Shareholders Are Hoping For More
Dec 07Dermapharm Holding SE Just Missed Earnings - But Analysts Have Updated Their Models
Nov 18Desglose de ingresos y gastos
Cómo gana y gasta dinero Dermapharm Holding. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
30 Sep 24 | 1,174 | 91 | 283 | 0 |
30 Jun 24 | 1,147 | 83 | 282 | 0 |
31 Mar 24 | 1,129 | 57 | 274 | 0 |
31 Dec 23 | 1,151 | 62 | 271 | 0 |
30 Sep 23 | 1,172 | 95 | 249 | 0 |
30 Jun 23 | 1,151 | 123 | 228 | 0 |
31 Mar 23 | 1,128 | 146 | 212 | 0 |
31 Dec 22 | 1,041 | 134 | 191 | 0 |
30 Sep 22 | 1,024 | 176 | 185 | 0 |
30 Jun 22 | 1,004 | 185 | 180 | 0 |
31 Mar 22 | 980 | 211 | 173 | 0 |
31 Dec 21 | 960 | 210 | 169 | 0 |
30 Sep 21 | 902 | 162 | 168 | 0 |
30 Jun 21 | 858 | 123 | 167 | 0 |
31 Mar 21 | 828 | 95 | 168 | 0 |
31 Dec 20 | 808 | 86 | 158 | 0 |
30 Sep 20 | 775 | 80 | 142 | 0 |
30 Jun 20 | 760 | 77 | 134 | 0 |
31 Mar 20 | 743 | 85 | 119 | 0 |
31 Dec 19 | 714 | 77 | 116 | 0 |
30 Sep 19 | 674 | 73 | 114 | 0 |
30 Jun 19 | 639 | 77 | 105 | 0 |
31 Mar 19 | 611 | 73 | 100 | 0 |
31 Dec 18 | 584 | 75 | 92 | 0 |
30 Sep 18 | 558 | 75 | 96 | 0 |
30 Jun 18 | 525 | 76 | 89 | 0 |
31 Mar 18 | 498 | 79 | 82 | 0 |
31 Dec 17 | 480 | 78 | 78 | 0 |
30 Sep 17 | 486 | 84 | 70 | 0 |
31 Dec 16 | 455 | 77 | 71 | 0 |
31 Dec 15 | 396 | 13 | 65 | 0 |
31 Dec 14 | 402 | 0 | 67 | 0 |
Ingresos de calidad: DMP tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio(7.7%) de DMP son inferiores a los del año pasado (8.1%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de DMP han crecido un 1.8% al año en los últimos 5 años.
Acelerando crecimiento: DMP ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.
Beneficios vs. Industria: DMP tuvo un crecimiento negativo de los beneficios (-4.6%) durante el año pasado, lo que dificulta la comparación con la media de la industria Pharmaceuticals (28.7%).
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de DMP (15.2%) se considera baja.